試す 金 - 無料
"Implementation of Rapid Microbiological Methods will play a vital role in contributing to the Global Health for drugs"
Bio Spectrum
|BioSpectrum India April 2025
The inaugural BioLuminescence 2025 event by Merck took place in Ahmedabad on February 20, serving as a pivotal platform to enhance engagement with regulatory bodies, key opinion leaders, and stakeholders in the pharmaceutical industry.
-
Dr Michael Miller, President, Microbiology Consultants, LLC
An internationally recognised microbiologist and subject matter expert in pharmaceutical microbiology, contamination control, Dr Michael Miller, President - Microbiology Consultants, LLC spoke about the Future of Pharma QC and how Rapid Microbiological Method (RMM) play a key role there.
What are some of the developments you have seen in quality control (QC) Microbiology from the past 10 years, some trends that stood out for you in this space?
There are a number of startups that have been pushing the envelope in microbial detection, quantification and identification and newer technologies that are miniaturised, such as lab-on-a-chip platforms, and real-time detection of microorganisms. I expect to see this trend continue in the foreseeable future.
What are the latest RMM technologies being developed to support pharmaceutical companies?
The science of biofluorescent particle counters (BFPC) has been around for a number of years. However, sterile pharma manufacturers are now validating these for routine use. They produce an autofluorescent unit (AFU) in real-time, allowing manufacturers to immediately react to excursions or out-of-trend findings for viable microorganisms, rather than retrospectively addressing these issues once incubation on standard plates have completed, which could be as long as a week since the batch was manufactured. And many of these systems are designed to capture the sampled air flow onto conventional media in the hopes of growing these for subsequent studies, such as microbial identification, which may help with investigations associated with the original contamination event. I also manage a catalogue of existing and next generation RMMs that is constantly changing as new technologies are introduced.
このストーリーは、Bio Spectrum の BioSpectrum India April 2025 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Bio Spectrum からのその他のストーリー
Bio Spectrum
Thermo Fisher Scientific invests Rs 160 Cr+ to expand Bengaluru R&D facility
Thermo Fisher Scientific's expanded Research and Development (R&D) Centre of Excellence was inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM).
1 min
December 2025
Bio Spectrum
Motorica strengthens India presence with appointment of Kavinder Beniwal as COO
Motorica, a Delhi-based medtech company specialising in assistive technologies and medical cybernetics, has announced the appointment of Kavinder Beniwal as Chief Operational Officer (COO) of Motorica India.
1 min
December 2025
Bio Spectrum
Cabinet approves major expansion of PG and UG medical education capacity
Union Cabinet chaired by the Prime Minister Narendra Modi has approved the Phase-Ill of the Centrally Sponsored Scheme (CSS) for strengthening and upgradation of existing State Government/ Central Government Medical Colleges/Standalone PG Institutes/ Government Hospitals for increasing 5,000 PG seats and extension of the CSS for upgradation of existing government medical colleges for increasing 5,023 MBBS seats with an enhanced cost ceiling of Rs 1.5 crore per seat.
1 min
December 2025
Bio Spectrum
Dr Sharvil Patel steps in as Indian Pharmaceutical Alliance President
The Indian Pharmaceutical Alliance (IPA) has announced a leadership transition, with Dr Sharvil Patel, Managing Director of Zydus Lifesciences and former Vice President of IPA, assuming the role of President.
1 min
December 2025
Bio Spectrum
PAG-led Sekhmet Pharmaventures announces appointment of Mukesh Agarwal as CFO
Hyderabad-based Sekhmet Pharmaventures, a fast-emerging global API/CDMO player led by leading Asia-focused investment firm PAG, has announced the appointment of Mukesh Agarwal as its new Chief Financial Officer (CFO).
1 min
December 2025
Bio Spectrum
Monash University Malaysia and Tata Chemicals forge healthcare researchfocused partnership
The importance of gastrointestinal health is a key focus for researchers and innovators, as highlighted by the partnership between Monash University Malaysia and Tata Chemicals Limited.
1 min
December 2025
Bio Spectrum
"India has the talent and ambition to lead globally in advanced therapies, biologics, and oncology"
Thermo Fisher Scientific has recently announced plans to make significant investments in India's biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. Central to this expansion strategy are two major facilities in Genome Valley, Hyderabad, i.e. Bioprocess Design Center (BDC), and Customer Experience Center (CEC). In addition, the company has invested more than Rs 160 crore this year to expand its R&D facility in Bengaluru. For further understanding on these new developments, BioSpectrum spoke in detail to Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific. Edited excerpts;
4 mins
December 2025
Bio Spectrum
"AI is a transformative enabler that's reshaping how science is conducted in labs"
2025 witnessed multiple new initiatives taken by Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, for the Indian market. These initiatives included establishment of an India Solutions Center in Manesar; and a Biopharma Experience Center in Hyderabad. 2025 also saw Nandakumar Kalathil stepping in as the new Country General Manager for Agilent India. With over 25 years of experience in the analytical industry, Nanda brings extensive expertise in leadership, team management, and customer relations. To find out more about the company's growth plans in 2026 in India, BioSpectrum interacted with Nandakumar Kalathil, Country General Manager for Agilent India in detail. Edited excerpts:
4 mins
December 2025
Bio Spectrum
Supporting India's Biopharma Expansion with Advanced, High-Performance Media
Kent Wang graduated from East China University of Science and Technology in Biochemical Engineering. He has over 12 years of experience in upstream biopharmaceutical process development, contributing to clinical projects including monoclonal antibodies, bispecific antibodies, and ADCs. He is well-versed in CHO cell metabolism and culture media characteristics, and has optimized critical quality attributes such as glycosylation, charge variants, fragmentation, aggregation, and amino acid oxidation. Previously at Shanghai Pharmaceuticals Group and 3S Bio, he now serves as Senior R&D Director at Duoning Biotech, focusing on serum-free cell culture media development. He established a comprehensive platform for media formulation and product development, leading his team to create a diverse portfolio of media for CHO, HEK293, insect, vaccine, hybridoma, and lymphocyte cell lines, leveraging cell metabolism insights and big data modeling.
4 mins
December 2025
Bio Spectrum
Corning and SGD Pharma inaugurate glass tubing facility in Telangana for pharma packaging
Corning Inc and SGD Pharma have announced the inauguration of a new glass tubing facility in Telangana, which will expand pharmaceutical manufacturing in the region.
1 min
December 2025
Listen
Translate
Change font size
